CD155 in Bladder Cancer

  • End date
    Jan 1, 2028
  • participants needed
  • sponsor
    Fudan University
Updated on 26 February 2022
bladder cancer
invasive bladder cancer
transitional cell carcinoma
bladder tumor


This research is designed to investigate the prognostic and predictive value of CD155 in muscle invasive bladder cancer.

Condition Bladder Cancer
Treatment Adjuvant chemotherapy
Clinical Study IdentifierNCT03789682
SponsorFudan University
Last Modified on26 February 2022


Yes No Not Sure

Inclusion Criteria

patients with non-metastatic muscle invasive bladder cancer
pathology confirmed urothelial carcinoma
underwent cystectomy and pelvic lymph node dissection

Exclusion Criteria

not enough tissue for immunohistochemistry
patients with a second neoplasm
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note